| Outcome Measures: |
Primary: Change of glycosylated hemoglobin(HbA1c), Change of HbA1c from baseline value to end of treatment, 12 weeks | Secondary: Percentage of patients achieving HbA1c <7%, Percentage of patients achieving HbA1c \<7% at Week 12, 12 weeks|Percentage of patients achieving HbA1c ≤6.5%, Percentage of patients achieving HbA1c ≤6.5% at Week 12, 12 weeks|HbA1c, Changes of HbA1c from baseline value at Weeks 2, 4, and 8, 2, 4, and 8 weeks|Fasting plasma glucose(FPG), Changes of fasting plasma glucose(FPG) from baseline value at Weeks 2, 4, 8, and 12., 2, 4, 8, and 12 weeks|2-hour postprandial glucose(2-h PPG), Changes of 2-hour postprandial glucose(2-h PPG) from baseline value at Weeks 4, 8, and 12., 4, 8, and 12 weeks|Insulin, Changes of insulin from baseline value at Weeks 4, 8, and 12, 4, 8, and 12 weeks|C-peptide, Changes of C-peptide from baseline value at Weeks 4, 8, and 12, 4, 8, and 12 weeks|Self-monitoring of blood glucose (SMBG), Changes of mean profile and mean increments from baseline value of the 7-point SMBG, 4, 8, and 12 weeks | Other: Body mass index(BMI), Changes of BMI from baseline value at Weeks 2, 4, 8, and 12., 2, 4, 8, and 12 weeks|Waist and hip circumferences and waist-to-hip ratio, Change of waist and hip circumferences and waist-to-hip ratio from baseline value at end of treatment(waist and hip circumferences will be used to calculate waist-to-hip ratio, 12 weeks|Blood pressure(both systolic and diastolic), Changes of blood pressure from baseline value at Weeks 2, 4, 8, and 12., 2, 4, 8, and 12 weeks|Blood lipid, Changes of blood lipid from baseline value at Weeks 2, 4, 8, and 12, 2, 4, 8, and 12 weeks
|
